Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Liposomal formulation of Cisplatinum
LiPlaCis · 1 trial · 2 indications
Primary Objective: Assessment of adverse events and laboratory abnormalities
| Arm | Type | Description |
|---|---|---|
| LiPlaCis | EXPERIMENTAL | Dose escalation of LiPlaCis - a liposomal formulation of cisplatin will be administered intravenously in cycles every 3 weeks on day 1, day 8. Upon the investigator's judgement the patient may continue treatment for more than 3 cycles when benefiting from the study drug. |
| Name | Type | Description |
|---|---|---|
| LiPlaCis | DRUG | LiPlaCis IV every 3 weeks on day 1, day 8 |
Inclusion Criteria: * Histological or cytological documented locally advanced or metastatic solid tumour relapsed on 2 or more different prior therapies. From step 5 and extension phase, population limited to Skin Cancer patients (non screened) or metastatic Breast Cancer patients or metastatic cas...
LiPlaCis is an investigational small molecule oncology drug developed by Allarity Therapeutics, Inc. (ticker ALLR). It has been studied in a Phase 1/2 clinical trial in patients with advanced or refractory solid tumors, with a Phase 2 part focused on metastatic breast cancer, prostate cancer and skin cancer.
LiPlaCis has been studied for the treatment of advanced or refractory solid tumors in its Phase 1 portion, and for metastatic breast cancer, prostate cancer and skin cancer in the Phase 2 part of its clinical program. It is investigational and has not been established as an approved therapy.
LiPlaCis is developed by Allarity Therapeutics, Inc., which trades under the ticker ALLR. The company sponsored the clinical study evaluating the drug in patients with advanced or refractory tumors.
LiPlaCis is in Phase 1 development. Its single clinical trial, NCT01861496, was a Phase 1/2 study, and the program is described as Phase 1. The trial has been completed, and no trials are currently active.
LiPlaCis has been evaluated in one clinical trial, NCT01861496, titled a Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours. The trial enrolled 50 patients in Denmark, was uncontrolled, and has been completed.